ImmunoVEX HSV2

Drug Profile

ImmunoVEX HSV2

Alternative Names: Genital herpes vaccine - Amgen; Herpes simplex virus vaccine - Amgen

Latest Information Update: 19 Mar 2011

Price : $50

At a glance

  • Originator BioVex
  • Developer Amgen
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 04 Mar 2011 BioVex has been acquired by Amgen
  • 05 Mar 2010 Phase-I clinical trials in Herpes simplex virus infections prevention in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top